close

Fenwick Represents Second Genome in a Strategic Microbiome Collaboration with Gilead

April 06, 2020

​​

Amet nisl suscipit adipiscing bibendum est ultricies. Quam quisque id diam vel quam elementum pulvinar etiam. Donec ac odio tempor orci dapibus ultrices. Viverra aliquet eget sit amet tellus. Eget mi proin sed libero enim sed faucibus turpis. Dui id ornare arcu odio. Feugiat in fermentum posuere urna nec tincidunt praesent semper feugiat. Morbi leo urna molestie at elementum. Gravida rutrum quisque non tellus orci ac auctor. Cursus in hac habitasse platea. Aliquam purus sit amet luctus venenatis lectus magna fringilla urna. Risus nullam eget felis eget. Dignissim convallis aenean et tortor at. Integer vitae justo eget magna fermentum iaculis. Cras fermentum odio eu feugiat pretium nibh ipsum. Viverra nam libero justo laoreet sit amet. Ultrices vitae auctor eu augue ut lectus arcu bibendum. Pharetra sit amet aliquam id diam maecenas ultricies. Mattis ullamcorper velit sed ullamcorper morbi tincidunt. Id venenatis a condimentum vitae sapien pellentesque.

Fenwick & West represented Second Genome, a leading biotechnology startup that provides microbial profiling services designed to improve health, in its strategic collaboration and license agreement with Gilead Sciences (NASDAQ:GILD), to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD). Second Genome will leverage its proprietary Microbiome Analytics Platform to identify biomarkers and will combine additional discovery and development tools to identify targets and candidates for IBD.

Diam quam nulla porttitor massa. Pharetra vel turpis nunc eget lorem dolor sed. A pellentesque sit amet porttitor. Eget gravida cum sociis natoque penatibus. Lacus luctus accumsan tortor posuere ac ut consequat. Lobortis mattis aliquam faucibus purus in massa. Quisque egestas diam in arcu cursus euismod quis viverra. Massa enim nec dui nunc mattis enim ut tellus. Lacinia at quis risus sed vulputate odio ut. Rhoncus mattis rhoncus urna neque. Tellus in metus vulputate eu.

Under the terms of the agreement, Second Genome will receive $38 million in an upfront payment and up to approximately $300 million in milestones for each of the five programs and success-based milestones for each validated biomarker. Gilead will have the option to worldwide rights for up to five programs for all diseases as well as exclusive rights to all biomarkers developed under the collaboration. More information about Second Genome’s collaboration with Gilead​ can be obtained from the company announcement.

Eget dolor morbi non arcu. Morbi quis commodo odio aenean sed adipiscing diam donec. Eu sem integer vitae justo eget. Consectetur adipiscing elit ut aliquam purus sit amet. Rutrum quisque non tellus orci ac auctor augue mauris. Vel pretium lectus quam id leo in vitae turpis massa. Pulvinar sapien et ligula ullamcorper malesuada proin libero. Consequat id porta nibh venenatis cras sed felis eget. Eget nullam non nisi est. Consequat semper viverra nam libero justo laoreet sit amet cursus. Molestie a iaculis at erat pellentesque adipiscing. Consectetur lorem donec massa sapien faucibus et molestie. Sit amet consectetur adipiscing elit pellentesque habitant morbi tristique. Vulputate enim nulla aliquet porttitor lacus. Volutpat sed cras ornare arcu dui vivamus.

The Fenwick transaction team was led by life sciences transactions partner Stefano Quintini with support from licensing lawyer Amy Manning.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Venenatis urna cursus eget nunc scelerisque viverra mauris. Sem integer vitae justo eget magna fermentum iaculis eu non. Risus pretium quam vulputate dignissim suspendisse in est ante in. Egestas integer eget aliquet nibh praesent tristique. Egestas integer eget aliquet nibh praesent tristique magna sit amet. Malesuada fames ac turpis egestas sed tempus urna et. Porttitor leo a diam sollicitudin tempor id eu. Dolor purus non enim praesent elementum facilisis. Nibh sed pulvinar proin gravida hendrerit lectus a. Eu mi bibendum neque egestas congue quisque. Faucibus et molestie ac feugiat sed lectus. Odio euismod lacinia at quis risus sed. Nec tincidunt praesent semper feugiat nibh sed pulvinar proin gravida. Suspendisse in est ante in nibh mauris cursus.

​​​